Approval is based on the CheckMate-77T trial, in which the Opdivo-based regimen demonstrated significantly longer event-free survival compared to the chemotherapy and placebo arm; a high pathologic complete response rate was also observed 1 Opdivo is the only approved PD-1 inhibitor for resectable NSCLC in both a neoadjuvant-only regimen and as part of a perioperative treatment regimen 1 This milestone adds to Bristol Myers... Read More

In the Phase 3b/4 PSORIATYK SCALP trial Sotyktu was superior to placebo across all primary and secondary endpoints at Week 16, with patients reporting significantly greater improvement in symptoms Safety profile in PSORIATYK SCALP was consistent with the established safety profile of Sotyktu In the real-world RePhlect registry of patients, six months of Sotyktu treatment was consistent with the efficacy outcomes observed in... Read More

COBENFY represents the first new pharmacological approach to treat schizophrenia in decades, with a mechanism of action distinct from current therapies Approval is supported by data from the EMERGENT clinical program demonstrating statistically significant reductions of schizophrenia symptoms The safety and tolerability... Read More

Final results from the DAYBREAK long-term extension study showed brain volume loss decreased during Phase 3 studies and was sustained with continuous Zeposia treatment for up to 5 years More than eight years of DAYBREAK data confirm established safety profile of Zeposia, with rates of treatment-emergent adverse events declining or stable over time PRINCETON, N.J. / Sep 18, 2024 / Business Wire / Bristol Myers Squibb (NYSE:... Read More

These data represent the longest reported median overall survival from a Phase 3 advanced melanoma trial; data selected for official ESMO press conference At ten years, more than 40% (43%) of patients treated with Opdivo plus Yervoy were alive; a decade ago, this patient population faced a survival rate of around 25% after only one year Data to be presented today as a mini oral and simultaneously published in The New England... Read More

PRINCETON, N.J. / Sep 12, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) will announce results for the third quarter of 2024 on Thursday, October 31, 2024. Company executives will review financial results and address inquiries from investors and analysts during a conference call beginning at 8:00 a.m. ET on the same date. Investors and the general public are invited to listen to a live webcast of the call at... Read More

PRINCETON, N.J. / Sep 10, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents ($0.60) per share on the $0.10 par value common stock of the company. The dividend is payable on November 1, 2024, to stockholders of record at the close of business on October 4, 2024. In addition, the Board of Directors has declared a quarterly... Read More

Data from proof-of-concept, randomized, Phase 2 RELATIVITY-104 trial exploring the combination of nivolumab, relatlimab (1:1) and chemotherapy as first-line treatment for stage IV or recurrent NSCLC; BMS initiating Phase 3 RELATIVITY-1093 trial Ten-year follow-up data from CheckMate -067 showed continued durable, long-term survival benefit of Opdivo ® (nivolumab) plus Yervoy ® (ipilimumab) in patients with advanced or... Read More

PRINCETON, N.J. / Sep 06, 2024 / Business Wire / With cancer patients top of mind, teams of Bristol Myers Squibb (NYSE: BMY) employees will relay Coast 2 Coast 4 Cancer (C2C4C) this year and cycle from Oregon to New Jersey with the goal of raising $1 million in support of the V Foundation for Cancer Research . Since the ride’s inception in 2014, Bristol Myers Squibb employees – many of whom have been personally impacted by... Read More

Cumulative analysis of data up to 3.5 years from EXPLORER-LTE showed consistent and sustained improvements in echocardiographic measures and symptoms, with no new safety signals observed CAMZYOS is the first and only approved cardiac myosin inhibitor that targets the source of symptomatic obstructive hypertrophic cardiomyopathy PRINCETON, N.J. / Sep 01, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced... Read More

PRINCETON, N.J. / Aug 27, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in September 2024. Christopher Boerner, Ph.D., Board Chair and Chief Executive Officer, and David Elkins, Executive Vice President, Chief Financial Officer, will take part in a fireside chat at the Morgan Stanley 22 nd Annual Global Healthcare Conference on... Read More

New analyses, including presentations on CAMZYOS ® (mavacamten), ELIQUIS ® (apixaban) and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases PRINCETON, N.J. / Aug 26, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research across its robust cardiovascular portfolio at the European Society of Cardiology (ESC) Congress, taking... Read More

Acceptance based on Phase 3 CheckMate -9DW trial results demonstrating improved survival with Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to investigator’s choice of lenvatinib or sorafenib in this patient population The U.S. Food and Drug Administration assigned a target action date of April 21, 2025 PRINCETON, N.J. / Aug 21, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food... Read More

Application based on the TRANSCEND FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile Breyanzi also received approval in Japan for the treatment of relapsed or refractory follicular lymphoma (FL) after one prior line of systemic therapy in patients with high-risk FL and after two or more lines of systemic therapy, making it the first and only CAR T treatment... Read More

Results Underscore Continued Progress on Commercial Execution, Driving the Growth Portfolio and Pipeline Advancement Second Quarter Revenues were $12.2 Billion, increasing 9% (+11% Adjusting for Foreign Exchange) Growth Portfolio Revenues were $5.6 Billion, increasing 18% (+21% Adjusting for Foreign Exchange) GAAP EPS was $0.83 and Non-GAAP EPS was $2.07; Includes Net Impact of $(0.04) Per Share for GAAP EPS and Non-GAAP EPS... Read More

The Application is based on Phase 3 CheckMate - 9DW trial results demonstrating improved survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population PRINCETON, N.J. / Jul 19, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that the European Medicines Agency (EMA) validated its Type II variation application for Opdivo ® (nivolumab) plus... Read More

PRINCETON, N.J. / Jul 08, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in Virtual Targeted Protein Degradation Day hosted by UBS. Robert Plenge, M.D., Ph.D., Executive Vice President, Chief Research Officer and Head of Research, will take part in a fireside chat on Monday, July 15, 2024. He will answer questions about the company beginning at 11:00 a.m. ET.... Read More

Approval based on results from the Phase 1/2 KRYSTAL-1 study where KRAZATI in combination with cetuximab showed an objective response rate of 34% in pretreated patients with locally advanced or metastatic CRC harboring a KRAS G12C mutation 1 Second FDA approval for KRAZATI - reinforcing its potential across tumor types PRINCETON, N.J. / Jun 21, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that the... Read More

Validation is based on results from CheckMate -67T, the first Phase 3 trial of the subcutaneous formulation of Opdivo to evaluate and demonstrate noninferior pharmacokinetics and efficacy vs. its intravenous formulation Application seeks approval for subcutaneous nivolumab formulation to treat multiple Opdivo adult solid tumor indications in the European Union PRINCETON, N.J. / Jun 21, 2024 / Business Wire / Bristol Myers... Read More

PRINCETON, N.J. / Jun 20, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) will announce results for the second quarter of 2024 on Friday, July 26, 2024. Company executives will review financial results and address inquiries from investors and analysts during a conference call beginning at 8:00 a.m. ET on the same date. Investors and the general public are invited to listen to a live webcast of the call at... Read More

PRINCETON, N.J. / Jun 18, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has elected independent director Michael R. McMullen to the Board, effective July 1, 2024. Mr. McMullen will serve as a member of the Audit Committee of the Board of Directors. “We are pleased to welcome Mr. Michael McMullen to our Board of Directors,” said Christopher Boerner, Ph.D., board chair and... Read More

PRINCETON, N.J. / Jun 18, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents ($0.60) per share on the $0.10 par value common stock of the company. The dividend is payable on August 1, 2024, to stockholders of record at the close of business on July 5, 2024. In addition, the Board of Directors has declared a quarterly dividend of... Read More

Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-na ï ve and TKI-pretreated patients across solid tumors , demonstrating clinically meaningful response rates in the TRIDENT-1 trial 1 This accelerated approval marks the second indication for Augtyro in the U.S. 1 PRINCETON, N.J. / Jun 13, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food... Read More

Late-breaking data to be presented at the 2024 American Society of Clinical Oncology (ASCO ® ) Annual Meeting Dual immunotherapy combination of Opdivo plus Yervoy demonstrated improved survival benefit compared to lenvatinib or sorafenib in this patient population Objective response rate (ORR) for Opdivo plus Yervoy was more than double that for lenvatinib or sorafenib, with median duration of response of 30 months... Read More

PRINCETON, N.J. / Jun 04, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Goldman Sachs 45 th Annual Global Healthcare Conference. Christopher Boerner, Ph.D., Board Chair and Chief Executive Officer, will take part in a fireside chat on Tuesday, June 11, 2024. He will answer questions about the company beginning at 11:20 a.m. ET. Investors and the general... Read More

Three-year follow-up results from TRANSFORM show ongoing event-free survival and durable responses with Breyanzi compared to standard of care Results from a subgroup analysis from mantle cell lymphoma cohort of TRANSCEND NHL 001 show Breyanzi demonstrated consistent clinical benefit regardless of number of prior lines of therapy, supporting use of Breyanzi in earlier lines of treatment Data from bridging therapy subgroup... Read More

Late-breaking exploratory analysis of the CheckMate -77T study of perioperative Opdivo shows improved event-free survival and pathologic complete response in stage III resectable NSCLC patients regardless of nodal status Four-year follow-up data from the CheckMate -816 study reinforce neoadjuvant Opdivo plus chemotherapy in patients with resectable NSCLC, presented in late-breaking session June 2 Five-year follow-up data... Read More

First presentation of data from Phase 3 KRYSTAL-12 study showed statistically significant and clinically meaningful improvement in progression-free survival with KRAZATI compared to standard of care chemotherapy Late-breaking data featured in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting PRINCETON, N.J. / Jun 01, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today... Read More

In the MCL cohort of TRANSCEND NHL 001, Breyanzi delivered responses in 85.3% of patients with a one-time infusion while demonstrating a consistent safety profile across clinical trials Breyanzi is the only CAR T cell therapy approved by the FDA for four distinct subtypes of non-Hodgkin lymphoma, bringing this personalized therapy to the broadest array of patients with B-cell malignancies PRINCETON, N.J. / May 30, 2024 /... Read More

Approval based on results from CheckMate -901, the first Phase 3 trial in this patient population with an immunotherapy-chemotherapy combination to demonstrate survival benefit versus standard-of-care chemotherapy alone First concurrent immunotherapy-chemotherapy combination approved for this patient population in the European Union PRINCETON, N.J. / May 29, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today... Read More

PRINCETON, N.J. / May 23, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology and hematology portfolio at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2024 Hybrid Congress. Data from more than 130 company-sponsored studies, investigator-sponsored studies, and collaborations showcase... Read More

Consistent with short-term studies, KarXT was not associated with clinically meaningful changes in movement disorder scale scores and a low incidence rate of extrapyramidal symptoms was reported over long-term trials in adults with schizophrenia In-trial qualitative interviews found that the majority of participants treated with KarXT in the long-term EMERGENT-5 trial perceived improvements in positive, negative and... Read More

The Company enters strategic collaboration with the Access to Oncology Medicines (ATOM) Coalition to expand access to immuno-oncology therapy Opdivo™ in select countries PRINCETON, N.J. / May 22, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced ASPIRE (Accessibility, Sustainability, Patient-centric, Impact, Responsibility and Equity), a 10-year strategy to advance access to our innovative treatments... Read More

Additional funding will be used to explore novel biology around the MMR pathway and accelerate progression of the lead program into candidate selection LONDON , May 22, 2024 /PRNewswire/ -- NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that Bristol Myers Squibb (NYSE: BMY) has joined its oversubscribed Series B extension round. The additional investment from Bristol Myers Squibb will... Read More

The national initiative, Live Your PosSCZible, is focused on elevating the voices of those with schizophrenia and their care partners to drive impactful conversations about the aspirations of the community Actor and author Taye Diggs and his sister, Christian, who was diagnosed with schizophrenia as a young adult, share their experiences alongside members of the schizophrenia community Initiative provides resources and tools... Read More

Updated Prescription Drug User Fee Act (PDUFA) goal date of December 29, 2024 PRINCETON, N.J. / May 21, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has reassigned the previously announced Prescription Drug User Fee Act (PDUFA) goal date of the Biologics License Application (BLA) for the subcutaneous formulation of Opdivo ® (nivolumab) co-formulated... Read More

Following four years of continuous Sotyktu treatment, clinical response was maintained in more than seven out of 10 patients for Psoriasis Area and Severity Index (PASI) 75 in the POETYK PSO long-term extension trial No new safety signals observed at Year 4 in the POETYK PSO long-term extension trial, consistent with the established Sotyktu safety profile PRINCETON, N.J. / May 16, 2024 / Business Wire / Bristol Myers Squibb... Read More

95.7% of patients responded to Breyanzi in the TRANSCEND FL trial Breyanzi provided sustained clinical benefit with median duration of response not reached and the majority (77.1%) of responders in ongoing response at 18 months Breyanzi is a personalized therapy with a differentiated profile, offering durable responses and a... Read More

PRINCETON, N.J. / May 10, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -73L trial did not meet its primary endpoint of progression-free survival (PFS) in unresectable, locally advanced stage III non-small cell lung cancer (NSCLC). CheckMate -73L evaluated Opdivo ® (nivolumab) with concurrent chemoradiotherapy (CCRT) followed by Opdivo plus Yervoy ® (ipilimumab) versus CCRT... Read More

PRINCETON, N.J. / May 07, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in May 2024. Ben Hickey, President, RayzeBio, Head of Mirati, will take part in a fireside chat at the Guggenheim Healthcare Talks Radiopharmaceuticals Day on Monday, May 13, 2024. He will answer questions about the company beginning at 11:00 a.m. ET. David... Read More

Application based on results from CheckMate -67T, the first Phase 3 trial of the subcutaneous formulation of nivolumab to evaluate and demonstrate noninferior pharmacokinetics, efficacy and consistent safety vs. its intravenous formulation Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor The FDA assigned a target action date of February 28, 2025 PRINCETON, N.J. / May... Read More

Application based on results from the CheckMate -8HW study, in which Opdivo plus Yervoy demonstrated statistically significant and clinically meaningful improvement in progression-free survival compared to investigator’s choice of chemotherapy European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with... Read More

Collaboration combines Repertoire's industry leading DECODE™ platform that uniquely maps the immune synapse to develop T cell targeted immune medicines with Bristol Myers Squibb's world-leading expertise in developing and commercializing innovative immune medicines Repertoire will receive an upfront payment of $65 million and is eligible to receive up to $1.8 billion in milestone and other payments and tiered royalties... Read More

Recommendation based on results from CheckMate -901, the first Phase 3 trial with an immunotherapy-chemotherapy combination to demonstrate a survival benefit versus standard-of-care chemotherapy alone in cisplatin-eligible adults with unresectable or metastatic urothelial carcinoma If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for this patient population in the EU A... Read More

Performance Reflects Execution and Actions to Strengthen the Company's Long-Term Growth Profile First Quarter Revenues were $11.9 Billion, increasing 5% (+6% Adjusting for Foreign Exchange) Growth Portfolio Revenues were $4.8 Billion, increasing 8% (+11% Adjusting for Foreign Exchange) Strengthened Long-Term Growth Profile Through Completion of Karuna Therapeutics, RayzeBio, Mirati Therapeutics, and SystImmune Transactions... Read More

Bristol Myers Squibb will utilize Cellares’ proprietary Cell Shuttle, a next-generation end-to-end, fully automated cell therapy manufacturing platform, for the clinical and commercial-scale manufacturing of select CAR T cell therapies Cellares, the world’s first Integrated Development and Manufacturing Organization (IDMO), will allocate multiple Cell Shuttles and its fully automated, high-throughput Cell Q systems across... Read More

Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program PRINCETON, N.J. / Apr 08, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced data from the cohorts of the Phase 1/ 2 KRYSTAL-1 study evaluating KRAZATI ® (adagrasib) in combination with cetuximab... Read More

Long-term treatment with KarXT was associated with continued improvements in symptoms of schizophrenia across all efficacy measures at 52 weeks More than 75% of participants achieved > 30% improvement in symptoms from baseline, as measured by the Positive and Negative Syndrome Scale (PANSS) total score, at one year Participants previously on placebo in acute trials experienced significant reduction of symptoms beginning at... Read More

KarXT demonstrated a favorable long-term metabolic profile where most patients experienced stability or improvements on metabolic parameters over 52 weeks of treatment A majority of patients (65%) experienced reductions in weight over the course of the trial, with a mean weight decrease of 2.6kg observed at one year Data show no significant changes related to prolactin or clinically meaningful changes in movement disorder... Read More

Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety profile Expanded approval brings this personalized CAR T cell therapy to more patients with relapsed or refractory multiple myeloma... Read More

Approval of Reblozyl is based on head-to-head, pivotal Phase 3 COMMANDS study, in which Reblozyl nearly doubled the percentage of patients achieving transfusion independence and hemoglobin increase, along with increased durability compared to epoetin alfa This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia and the first therapy to demonstrate... Read More

Company builds on its strengths to advance patient access, product innovation, culture and inclusion and diversity PRINCETON, N.J. / Apr 02, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today published its 2023 Environmental, Social, and Governance (ESG) Report detailing the company’s meaningful progress, evolved strategy, and aspirational goals toward its ESG efforts. The company’s ESG strategy is embedded in its... Read More

Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS G12C -Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer PRINCETON, N.J. / Mar 28, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that the pivotal Phase 3 KRYSTAL-12 study, evaluating KRAZATI ®... Read More

PRINCETON, N.J. / Mar 28, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced an update following the initial analysis of results from the first of two induction studies in the Phase 3 YELLOWSTONE clinical trial program evaluating Zeposia (ozanimod) in adult patients with moderate to severe active Crohn’s disease. The study did not meet its primary endpoint of clinical remission at Week 12. The safety... Read More

Company Awards $1.8M in Grants to Eight Organizations in Brazil, India, Thailand and the United Kingdom PRINCETON, N.J. / Mar 26, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today unveiled a $1.8 million initiative to advance health equity by addressing social determinants of health (SDoH) in four countries with underserved patient needs, including Brazil, India, Thailand, and the United Kingdom. The new health... Read More

Analysis from a 10-month post-launch evaluation of the REMS Program finds 2.8% incidence of LVEF <50% in over 1500 patients, strengthening the safety profile of CAMZYOS ® (mavacamten) for NYHA class II-III obstructive hypertrophic cardiomyopathy Real-world data reaffirm therapeutic value and treatment benefit of CAMZYOS in improving cardiac symptoms and NYHA class in patients with obstructive hypertrophic cardiomyopathy... Read More

Abecma demonstrated superiority over standard regimens in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety profile with mostly low-grade and transient occurrences of cytokine release syndrome and neurotoxicity Approval reinforces Bristol Myers Squibb’s commitment to bring the transformative potential of cell therapy into earlier lines of treatment... Read More

Opdivo plus Yervoy demonstrates statistically significant and clinically meaningful improvement in overall survival compared to investigator’s choice of sorafenib or lenvatinib PRINCETON, N.J. / Mar 20, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -9DW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for patients with advanced... Read More

PRINCETON, N.J. / Mar 19, 2024 / Business Wire / Award-winning actor Ted Danson, who lives with plaque psoriasis, teams up with Bristol Myers Squibb for the inspiring “ SO, Have You Found It? ” campaign. This initiative spotlights the resilience of around two million Americans with moderate to severe plaque psoriasis, aiming... Read More

KarXT, Karuna’s Lead Asset, Is a Potential First-in-Class Treatment for Schizophrenia with Multi-Billion Dollar Sales Potential Across Multiple Indications PRINCETON, N.J. / Mar 18, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Karuna Therapeutics, Inc. (“Karuna”). With the acquisition's completion, Karuna shares have ceased trading on the Nasdaq... Read More

The supplemental Biologics License Application for Abecma in this indication remains under review with the FDA; Abecma has been approved in Japan and Switzerland and received a positive CHMP Opinion by the European Medicines Agency based on KarMMa-3 PRINCETON, N.J. & CAMBRIDGE, Mass. / Mar 15, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) today announced that the U.S. Food and... Read More

Breyanzi offers a personalized treatment option delivered as a one-time infusion that provides deep and durable responses for patients with relapsed or refractory CLL or SLL who have historically had no standard of care In TRANSCEND CLL 004, the first pivotal multicenter trial to evaluate a CAR T cell therapy in patients with... Read More

PRINCETON, N.J. / Mar 11, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) will announce results for the first quarter of 2024 on Thursday, April 25, 2024. Company executives will review financial results and address inquiries from investors and analysts during a conference call beginning at 8:00 a.m. ET on the same date. Investors and the general public are invited to listen to a live webcast of the call at... Read More

In the Phase 3 CheckMate -901 trial, Opdivo with cisplatin and gemcitabine demonstrated a statistically significant improvement in overall survival and progression-free survival compared to cisplatin-gemcitabine alone 1 This is the first concurrent immunotherapy-chemotherapy combination approved for this patient population in the U.S. PRINCETON, N.J. / Mar 07, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today... Read More

PRINCETON, N.J. / Mar 06, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in March 2024. Samit Hirawat, M.D., executive vice president, chief medical officer, Drug Development, will take part in a fireside chat at the Leerink Partners Global Biopharma Conference 2024 in Miami Beach, Florida, on Wednesday, March 13, 2024. He will... Read More

PRINCETON, N.J. / Mar 01, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents ($0.60) per share on the $0.10 par value common stock of the company. The dividend is payable on May 1, 2024, to stockholders of record at the close of business on April 5, 2024. In addition, the Board of Directors has declared a quarterly dividend of... Read More

Sustained efficacy was confirmed with an annualized relapse rate of 0.098 and 67% of patients were relapse-free at six years Safety was consistent with prior findings and the established safety profile of Zeposia with nearly 10 years of clinical experience In a separate DAYBREAK analysis, nearly 97% of followed patients were relapse-free at 90 days post Zeposia discontinuation; patients that did relapse showed no evidence of... Read More

PRINCETON, N.J. / Feb 26, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the TD Cowen 44 th Annual Health Care Conference in Boston, Massachusetts, on Monday, March 4, 2024. Roland Chen, M.D., senior vice president, Immunology, Cardiovascular & Neuroscience development, will answer questions about the company during a fireside chat at 9:50 a.m. ET. Investors and... Read More

Adds RYZ101, an IND Engine and Manufacturing Capability, to BMS PRINCETON, N.J. / Feb 26, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ: RYZB). With the completion of the acquisition, RayzeBio shares have ceased trading on the NASDAQ Global Market and RayzeBio is now a wholly owned subsidiary of Bristol Myers Squibb. “We... Read More

Approval by European Commission would expand Reblozyl’s indication to include first-line treatment of anemia in adults with MDS in Europe In the pivotal Phase 3 COMMANDS study, Reblozyl nearly doubled the percentage of patients achieving primary endpoint of both transfusion independence and hemoglobin increase vs. epoetin alfa PRINCETON, N.J. / Feb 23, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced... Read More

PRINCETON, N.J. / Feb 23, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that its previously announced tender offer (the “Offer”) to acquire all of the outstanding shares of RayzeBio, Inc. (Nasdaq: RYZB) common stock for a purchase price of $62.50 per share in cash, or approximately $4.1 billion, expired at one minute after 11:59 p.m., Eastern Time, on February 22, 2024 (the “Expiration Time”).... Read More

U.S. FDA has assigned a target action date of June 21, 2024 Application based on results from the Phase 1/2 KRYSTAL-1 study PRINCETON, N.J. / Feb 20, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental new drug application (sNDA) for KRAZATI ® (adagrasib) in combination with cetuximab for the treatment of... Read More

PRINCETON, N.J. / Feb 14, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that it has priced a public offering (the “Offering”) of senior unsecured notes in a combined aggregate principal amount of $13 billion (collectively, the “Notes”). The Notes will be issued in nine tranches: (i) $500,000,000 in aggregate principal amount of floating rate notes due 2026, (ii) $1,000,000,000 in aggregate principal... Read More

PRINCETON, N.J. / Feb 14, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that it recently became aware of an unsolicited “mini-tender” offer by Tutanota LLC (“Tutanota”) to purchase up to five hundred thousand shares of Bristol Myers Squibb’s common stock, representing significantly less than one percent of Bristol Myers Squibb’s common stock outstanding, at an offer price of $55 per share (“Offer... Read More

Application based on results from the TRIDENT-1 and CARE trials, in which Augtyro demonstrated clinically meaningful response rates If approved, Augtyro will provide a new, next-generation option for patients with NTRK-positive locally advanced or metastatic solid tumors who have high unmet medical needs The U.S. Food and Drug Administration assigned a target action date of June 15, 2024 PRINCETON, N.J. / Feb 14, 2024 /... Read More

PRINCETON, N.J. & SAN DIEGO / Feb 12, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (Nasdaq: RYZB) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, in connection with Bristol Myers Squibb’s previously announced tender offer to acquire all of the outstanding shares of RayzeBio common stock for a purchase price of... Read More

Applications based on results from CheckMate -77T, the company’s second positive Phase 3 randomized trial with an immunotherapy-based combination for the treatment of non-metastatic non-small cell lung cancer The perioperative Opdivo-based regimen demonstrated significant improvement in event-free survival compared to neoadjuvant chemotherapy and placebo followed by surgery and adjuvant placebo The U.S. Food and Drug... Read More

Bristol Myers Squibb Company ranks in top 10 of Pharmaceutical and Biotech Sector on the issues Americans care about most PRINCETON, N.J. / Feb 05, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) is honored to announce it has been recognized as One of America's Most JUST Companies. The ranking, presented by JUST Capital and CNBC, recognized BMS for its commitment to key social responsibilities, including employees,... Read More

PRINCETON, N.J., & CAMBRIDGE, Mass. / Feb 05, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) today announced that a notice was published in the Federal Register that the U.S. Food and Drug Administration (FDA) will convene a virtual meeting of the Oncologic Drugs Advisory Committee (ODAC) on March 15, 2024, to review data supporting the supplemental Biologics License Application... Read More

Results Reflect Continued Strength of In-Line and New Products, Pipeline Execution and Business Development Activity, Supporting Growth Momentum into 2024 Reports Fourth Quarter Revenues of $11.5 Billion; GAAP EPS of $0.87 and Non-GAAP EPS of $1.70 In-Line and New Product Portfolio Revenues Increased 9% to $9.8 Billion Reports Full-Year Revenues of $45.0 Billion; GAAP EPS of $3.86 and Non-GAAP EPS of $7.51 In-Line and New... Read More

U.S. FDA grants both FL and MCL applications Priority Review Applications based on results from TRANSCEND FL and TRANSCEND NHL 001, in which Breyanzi demonstrated clinically meaningful benefit with deep and durable responses Multiple regulatory applications underscore Bristol Myers Squibb’s commitment to advancing Breyanzi, a differentiated CAR T cell therapy, for more patients across the broadest array of B-cell... Read More

CheckMate -67T is the first Phase 3 trial of the subcutaneous formulation of Opdivo to evaluate and demonstrate noninferior pharmacokinetics, efficacy and safety vs. its intravenous formulation Subcutaneous nivolumab demonstrated noninferior pharmacokinetics (co-primary endpoints) and objective response rate (key powered secondary endpoint) compared to intravenous Opdivo Results from the Phase 3 CheckMate -67T trial will be... Read More

Recommendation for approval based on Phase 3 KarMMa-3 study in which Abecma demonstrated superiority over standard regimens, significantly improved progression-free survival and a well-established safety profile with mostly low-grade occurrences of cytokine release syndrome and neurotoxicity This is the first positive CHMP opinion in earlier lines of therapy for a chimeric antigen receptor (CAR) T cell therapy in the... Read More

PRINCETON, N.J. / Jan 23, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Mirati Therapeutics, Inc. ® (“Mirati”). With the completion of the acquisition, Mirati shares have ceased trading on the NASDAQ Global Select Market and Mirati is now a wholly owned subsidiary of Bristol Myers Squibb. “The closing of the Mirati transaction is a significant... Read More

Patients with previously untreated advanced or metastatic renal cell carcinoma treated with Opdivo plus Yervoy experienced a 28% reduction in the risk of death vs. sunitinib at eight years from the start of treatment, regardless of risk group The dual immunotherapy combination showed improved survival and durable responses compared to sunitinib among intermediate- and poor-risk patients, as well as all randomized patients... Read More

Opdivo in combination with CABOMETYX reduced the risk of death by 23% in the first-line treatment of advanced renal cell carcinoma vs. sunitinib Four-year results demonstrating continued benefits with immunotherapy-tyrosine kinase inhibitor combination to be shared in an oral presentation at ASCO GU 2024 PRINCETON, N.J. & ALAMEDA, Calif. / Jan 22, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) and Exelixis, Inc.... Read More

First presentation of data from the Phase 3 randomized trial shows statistically significant and clinically meaningful improvement in progression-free survival with Opdivo plus Yervoy compared to chemotherapy as first-line treatment in this patient population Opdivo plus Yervoy is the first dual immunotherapy regimen to demonstrate significant efficacy benefit compared to chemotherapy as first-line treatment in MSI-H/dMMR... Read More

First presentation of results from Phase 3 CheckMate -67T trial with subcutaneous formulation of Opdivo (nivolumab and hyaluronidase) to be shared in a late-breaking oral presentation Four-year data from CheckMate -9ER and unprecedented eight-year data from CheckMate -214 will confirm durable outcomes with Opdivo-based combinations for patients with advanced renal cell carcinoma First disclosure of clinical outcomes from... Read More

Application based on data from the registrational TRIDENT-1 and CARE trials showing robust responses and durable activity in these patient populations If approved, repotrectinib will offer a potential best-in-class treatment for patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer and a new option for patients with NTRK-positive solid tumors, in the European Union PRINCETON, N.J. / Jan 02,... Read More

Transaction Brings RayzeBio’s Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs, to Bristol Myers Squibb’s Leading Oncology Franchise Lead Program, RYZ101, in Phase 3 Development for Treatment of Gastroenteropancreatic Neuroendocrine Tumors and Early-stage Development for Treatment of Small Cell Lung Cancer and Potentially Other Tumor Types Gains Robust... Read More

Transaction Delivers KarXT, a First-in-Class M1 / M4 Muscarinic Receptor Agonist, with Differentiated Efficacy and Safety KarXT Is a Potential First-in-Class Treatment for Schizophrenia and as an Adjunctive Therapy, and First-in-Disease Treatment for Alzheimer’s Disease Psychosis, with Promise in Additional Neuropsychiatric and Neurodegenerative Indications KarXT Is Expected to Launch in the U.S. for the Treatment of... Read More

PRINCETON, N.J. / Dec 22, 2023 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at J.P. Morgan’s 42 nd Annual Healthcare Conference in San Francisco, California, on Monday, January 8, 2024. Christopher Boerner, Ph.D. , chief executive officer, will make a formal presentation and answer questions about the company at 7:30 a.m. PST/10:30 a.m. EST. The event will be webcast... Read More

PRINCETON, N.J. / Dec 20, 2023 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the 2024 Goldman Sachs Healthcare C-Suite Unscripted Conference in New York City on Thursday, January 4, 2024. Adam Lenkowsky, executive vice president, chief commercialization officer, will answer questions about the company during a fireside chat at 11 a.m. ET. Investors and the general... Read More

PRINCETON, N.J. / Dec 15, 2023 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that the Phase 3 RELATIVITY-123 trial evaluating the fixed-dose combination of nivolumab and relatlimab for the treatment of microsatellite stable (MSS) metastatic colorectal cancer (mCRC) patients whose disease has progressed following at least one, but no more than four, prior lines of therapy for metastatic disease will be... Read More

PRINCETON, N.J. / Dec 15, 2023 / Business Wire / Bristol Myers Squibb (NYSE: BMY) will announce results for the fourth quarter of 2023 on Friday, February 2, 2024. Company executives will review financial results and address inquiries from investors and analysts during a conference call beginning at 8:00 a.m. ET on the same date. Investors and the general public are invited to listen to a live webcast of the call at... Read More

Companies to leverage Terray's tNova drug discovery platform to identify small molecule therapeutics against targets of interest. The collaboration includes an upfront payment and performance-based milestone payments, as well as royalties on global net sales of products. LOS ANGELES , Dec. 14, 2023 /PRNewswire/ -- Terray Therapeutics, a biotechnology company integrating scale experimentation and generative AI to improve the... Read More

Phase 1b DLBCL-001 study reinforces promising activity and combinability of golcadomide with R-CHOP in patients with previously untreated aggressive B-cell lymphoma Phase 1/2 CC-99282-NHL-001 study demonstrates activity and combinability with rituximab in heavily pretreated patients with diffuse large B-cell lymphoma PRINCETON, N.J. / Dec 11, 2023 / Business Wire / Bristol Myers Squibb (NYSE: BMY) announced the results of... Read More

Updated results highlight the range of differentiated research platforms across BMS’ multiple myeloma pipeline, including cell therapy and protein degradation Data will be presented for first-in-class GPRC5D CAR T BMS-986393, novel CELMoD™ agent mezigdomide, and unique 2+1 bispecific T cell engager alnuctamab PRINCETON, N.J. / Dec 11, 2023 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced updated results... Read More

At median follow-up of more than 30 months, Abecma maintained a 51% reduction in risk of disease progression or death with median PFS of 13.8 months compared with 4.4 months for standard regimens Responses were significantly improved with Abecma and continued to deepen over time with a complete response rate of 44% vs. 5% for standard regimens with consistent benefit observed across subgroups In the KarMMa-3 study, the... Read More

SystImmune and Bristol Myers Squibb to co-develop and co-commercialize BL-B01D1 in the United States; SystImmune to retain exclusive rights in Mainland China and Bristol Myers Squibb to gain an exclusive license in the rest of the world BL-B01D1 is a potentially first-in-class bispecific EGFRxHER3 ADC with potential to treat patients with lung and breast cancer, with opportunities to expand into additional tumor types This... Read More